Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36108662

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Oct
First author
O'Brien M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Dec;23(12):e528. doi: 10.1016/S1470-2045(22)00652-0.
    note
    Source null
    related pmid
    36455577
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Dec;23(12):e529. doi: 10.1016/S1470-2045(22)00682-9.
    note
    Source null
    related pmid
    36455578
    relationship
    Comment in

Authors and identifiers

  1. name
    O'Brien M
    type
    Author
  2. name
    Paz-Ares L
    type
    Author
  3. name
    Marreaud S
    type
    Author
  4. name
    Dafni U
    type
    Author
  5. name
    Oselin K
    type
    Author
  6. name
    Havel L
    type
    Author
  7. name
    Esteban E
    type
    Author
  8. name
    Isla D
    type
    Author
  9. name
    Martinez-Marti A
    type
    Author
  10. name
    Faehling M
    type
    Author
  11. name
    Tsuboi M
    type
    Author
  12. name
    Lee JS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    O'Brien M
    type
    Author
  2. name
    Paz-Ares L
    type
    Author
  3. name
    Marreaud S
    type
    Author
  4. name
    Dafni U
    type
    Author
  5. name
    Oselin K
    type
    Author
  6. name
    Havel L
    type
    Author
  7. name
    Esteban E
    type
    Author
  8. name
    Isla D
    type
    Author
  9. name
    Martinez-Marti A
    type
    Author
  10. name
    Faehling M
    type
    Author
  11. name
    Tsuboi M
    type
    Author
  12. name
    Lee JS
    type
    Author
bibliography ids
  1. nci-bib-5bafe0c1dbcca5582a7542aa
book metadata
content sha256
a84c18b07c7fcd3821ce2f2c1aed701a3efebef5690a9c3623868c8a7040fe50
document type
citation
dois
  1. 10.1016/S1470-2045(22)00518-6
electronic publication date
display
2022 Sep 12
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36108662
immutable id
pubmed:36108662@a84c18b07c7fcd3821ce2f2c1aed701a3efebef5690a9c3623868c8a7040fe50
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1274-1286
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Dec;23(12):e528. doi: 10.1016/S1470-2045(22)00652-0.
    note
    Source null
    related pmid
    36455577
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Dec;23(12):e529. doi: 10.1016/S1470-2045(22)00682-9.
    note
    Source null
    related pmid
    36455578
    relationship
    Comment in
outcomes validated
false
pmid
36108662
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
f68b38e2d3d6e8b2c4f1df04fef315f70bc6d935a88e36f05302542f898fdeb7
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Oct
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36108662/
title
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

Preserved source evidence · Not medical advice